Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Consensus

Hold

Average target

$115.25

Implied upside

—

Analysts

28

Why Is ILMN Essentially Flat Today?

Illumina shares are showing minimal movement today, up just $0.02 (0.01%), as investors digest mixed signals from the company's BioInsight AI rollout and broader headwinds affecting the genomics sector. The stock appears caught between cautious optimism about new product launches and sector-wide weakness affecting both Illumina and peer companies like Twist Bioscience.

Bottom line: Illumina is trading flat today as investors balance excitement over the company's BioInsight AI launch against near-term sector headwinds affecting genomics and AI stocks broadly. While the company's long-term transformation toward AI-powered services and its proven track record remain compelling, near-term weakness in the sector may persist until market sentiment improves; investors should monitor adoption rates for BioInsight AI and any shifts in sector sentiment as key catalysts ahead.